A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Key Inclusion Criteria:

• Male or nonpregnant female, age ≥18 years to <85 years.

• Body mass index (BMI) ≥18 to <35 kg/m2; weight ≥50 kg at Screening (BMI ≥ 18 to < 40kg/m2 is permitted for participants < 50 years).

• Diagnosed with hypertrophic cardiomyopathy at the time of Screening consistent withcurrent American College of Cardiology Foundation/American Heart AssociationGuidelines.

• LVOT peak gradient ≥ 50 mmHg measured at rest or during the Valsalva maneuver asdetermined by echocardiography at Screening (Part A, B and D oHCM only).

• LVOT peak gradient < 30 mmHg measured at rest and < 50 mmHg measured during theValsalva maneuver as determined by echocardiography at Screening (Part C and D nHCMonly).

• Documented left ventricular ejection fraction (LVEF) ≥ 0.60 at Screening.

• New York Heart Association (NYHA) Classification II-III at Screening.

• Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) < 85 atScreening.

• NT-proBNP ≥ 300 pg/mL (NT-proBNP ≥ 225 pg/mL is permitted for African Americanparticipants) (Part C and D nHCM only).

Key Exclusion Criteria:

• Invasive septal reduction therapy < 180 days prior to or during Screening.

• Documented history of active or untreated obstructive coronary artery disease duringScreening or treated for obstructive coronary artery disease < 180 days prior toScreening.

• Documented history of myocardial infarction with residual wall motion abnormalities < 180 days prior to or during Screening.

• Significant valvular heart disease (moderate or greater aortic stenosis orregurgitation, moderate or greater mitral stenosis or regurgitation not due tosystolic anterior motion of the mitral valve)

• History of LV systolic dysfunction (LVEF < 0.45) or stress cardiomyopathy at anytime.

• Known or suspected infiltrative or storage disorder causing cardiac hypertrophy thatmay mimic HCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LVhypertrophy.

• A history of unexplained syncope <180 days prior to or during Screening.

• A history of sustained ventricular tachyarrhythmia or sudden cardiac arrest < 180days prior or during Screening.

• A history of known appropriate implantable cardioverter defibrillator (ICD)discharge <180 days prior to or during Screening or ICD implanted < 14 days prior toScreening.

• History of permanent AF or atrial flutter. Documented AF or atrial flutter requiringrhythm restoring treatment < 180 days prior to Screening Visit (participants withdocumented AF or atrial flutter requiring rhythm restoring treatment ≥ 180 daysprior to Screening require adequate anticoagulation.)

• Fridericia-corrected QT interval (QTcF) ≥480 ms or any other ECG abnormalityconsidered by the Investigator or Medical Monitor to pose a risk to participantsafety at Screening (QTcF < 530 ms is permitted for participants with documentedbundle branch blockage (BBB) and/or cardiac pacing).

• Receiving a CMI (e.g., Camzyos® [mavacamten] or aficamten) < 90 days prior toScreening.